FDA Approves Nasonex 24HR Allergy (mometasone furoate) Nasal Spray for OTC Use
DUBLIN, March 17, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration for the over-the-counter use of Nasonex® 24HR Allergy (mometasone furoate monohydrate 50mcg). This approval marks the first branded Rx-to-OTC switch for the Company and paves the way for Nasonex® to enter the OTC marketplace. Perrigo expects to begin offering Nasonex® 24HR Allergy later this year.
Perrigo Executive Vice President & President, Consumer Self-Care Americas, Jim Dillard commented, "This first Rx-to-OTC switch for Nasonex® represents our continued focus on providing quality, affordable self-care products that consumers know and trust. It also epitomizes the strength of our internal innovation, R&D and regulatory capabilities. Successfully bringing Rx-to-OTC switches to market expands offerings available to consumers, enhances offerings for our retail partners and continues to differentiate Perrigo in the marketplace."
*NASONEX® is a registered trademark of Organon LLC and is used by Perrigo Company plc and its affiliates under license.
Perrigo Company plc (NYSE: PRGO) is a leading provider of Quality, Affordable Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Led by its consumer self-care strategy, Perrigo is the largest store brand OTC player in the U.S. in the categories in which it competes through more than 9,000 SKUs under customer 'own brand' labels. Additionally, Perrigo is a Top 10 OTC company by revenue in Europe, where it markets more than 200 branded OTC products throughout 28 countries. Visit Perrigo online at www.perrigo.com.
SOURCE Perrigo Company plc
Posted: March 2022